文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

术后放疗及预后模型在腮腺原发性鳞状细胞癌中的作用

The Role of Postoperative Radiotherapy and Prognostic Model in Primary Squamous Cell Carcinoma of Parotid Gland.

作者信息

Qiu Wenlong, Yang Yong, Sun Shiran, Zhou Fengge, Xu Yi, Luo Xi, Wang Zekun, He Meilin, Liu Yang, Yi Junlin

机构信息

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Front Oncol. 2021 Feb 15;10:618564. doi: 10.3389/fonc.2020.618564. eCollection 2020.


DOI:10.3389/fonc.2020.618564
PMID:33659214
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7919850/
Abstract

BACKGROUND: Primary squamous cell carcinoma of parotid gland (parotid SCC) is a high malignant histologic subtype of parotid cancers with aggressive clinical presentation. However, the clinical features and survival benefit of postoperative radiotherapy (PORT) for primary parotid SCC are not well known. METHODS: A retrospective population-based study was performed to identify the role of PORT in parotid SCC patients diagnosed between 1975 and 2016 from SEER database. A prognostic risk model was established based on patient clinical features, including age, tumor stage, and node involvement status. Patients were stratified into high, intermediate, and low risk according to this model. The survival benefit of radiotherapy was compared in the whole cohort and different risk groups. RESULTS: Nine hundred thirty-one parotid SCC patients were extracted from SEER database, 634 (68.1%) in the RT group and 286 (30.7%) in the non-RT group. Overall, 503 (54.0%) deaths occurred, with a median follow-up of 84 months, the 5-year OS was 43.6% in the whole cohort, 47.7 35.9% in patients with/without PORT (P = 0.005), and 58.9 38.8 27.1% in low-, intermediate-, and high-risk group (P < 0.001). Compared with surgery alone, PORT significantly improved the OS of patients with medium risk (47.5 20.6, P < 0.001), whereas not in the low risk (61 54%, P = 0.710) and high (25.6 28.7%, P = 0.524). CONCLUSION: This prognostic model can separate the patients with parotid squamous cell carcinoma into different risk. PORT significantly improved the OS of patients with intermediate risk, whereas high-risk group may need more intensive treatment strategies.

摘要

背景:腮腺原发性鳞状细胞癌(腮腺鳞癌)是腮腺癌中具有侵袭性临床表现的高恶性组织学亚型。然而,原发性腮腺鳞癌术后放疗(PORT)的临床特征和生存获益尚不清楚。 方法:进行一项基于人群的回顾性研究,以确定PORT在1975年至2016年间从监测、流行病学和最终结果(SEER)数据库诊断的腮腺鳞癌患者中的作用。基于患者的临床特征,包括年龄、肿瘤分期和淋巴结受累情况,建立了一个预后风险模型。根据该模型,将患者分为高、中、低风险组。比较了整个队列和不同风险组放疗的生存获益。 结果:从SEER数据库中提取了931例腮腺鳞癌患者,放疗组634例(68.1%),非放疗组286例(30.7%)。总体而言,发生503例(54.0%)死亡,中位随访84个月,整个队列的5年总生存率为43.6%,接受/未接受PORT的患者分别为47.7%和35.9%(P = 0.005),低、中、高风险组分别为58.9%、38.8%和27.1%(P < 0.001)。与单纯手术相比,PORT显著改善了中度风险患者的总生存率(47.5%对20.6%,P < 0.001),而低风险(61%对54%,P = 0.710)和高风险(25.6%对28.7%,P = 0.524)患者则未改善。 结论:该预后模型可将腮腺鳞状细胞癌患者分为不同风险组。PORT显著改善了中度风险患者的总生存率,而高风险组可能需要更强化的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cceb/7919850/4f86673272f6/fonc-10-618564-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cceb/7919850/c373f2017798/fonc-10-618564-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cceb/7919850/18b1f2972a48/fonc-10-618564-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cceb/7919850/babbb083df14/fonc-10-618564-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cceb/7919850/4f86673272f6/fonc-10-618564-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cceb/7919850/c373f2017798/fonc-10-618564-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cceb/7919850/18b1f2972a48/fonc-10-618564-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cceb/7919850/babbb083df14/fonc-10-618564-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cceb/7919850/4f86673272f6/fonc-10-618564-g004.jpg

相似文献

[1]
The Role of Postoperative Radiotherapy and Prognostic Model in Primary Squamous Cell Carcinoma of Parotid Gland.

Front Oncol. 2021-2-15

[2]
Subgroups of parotid gland infiltrating ductal carcinoma benefit from postoperative radiotherapy: a population-based study.

Future Oncol. 2019-1-22

[3]
Postoperative radiotherapy improves overall survival in patients with primary squamous cell carcinoma of the breast.

Asia Pac J Clin Oncol. 2021-12

[4]
Parotid metastasis--an independent prognostic factor for head and neck cutaneous squamous cell carcinoma.

J Plast Reconstr Aesthet Surg. 2006

[5]
Primary squamous cell carcinoma of the parotid gland.

Am J Otolaryngol. 2001

[6]
Parotid and neck metastases from cutaneous squamous cell carcinoma of the head and neck.

Am J Surg. 1995-11

[7]
Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland.

Head Neck. 2002-5

[8]
Primary squamous cell carcinoma of the parotid gland: clinicopathological characteristics, treatment, and prognosis.

Int J Oral Maxillofac Surg. 2021-2

[9]
Patterns of lymph node metastasis of parotid cancer.

Auris Nasus Larynx. 2016-8

[10]
Prognostic factors for squamous cell cancer of the parotid gland: an analysis of 2104 patients.

Head Neck. 2015-1

引用本文的文献

[1]
A nomogram to predict postoperative overall and cancer specific survival in patients with primary parotid squamous cell carcinoma: a population based study.

Sci Rep. 2025-2-25

[2]
Nomogram-Based Prediction of Overall and Disease-Specific Survival in Patients With Postoperative Major Salivary Gland Squamous Cell Carcinoma.

Technol Cancer Res Treat. 2022

本文引用的文献

[1]
Oncologic outcome and potential prognostic factors in primary squamous cell carcinoma of the parotid gland.

BMC Cancer. 2019-7-31

[2]
Clinical and radiobiological consideration of cyclical hypofractionated radiation therapy also known as QUAD Shot for neglected skin cancer disfiguring the face of a non-compliant patient who was refusing surgery and protracted radiation therapy: case report.

Radiat Oncol J. 2019-6

[3]
Role of intraparotid node metastasis in mucoepidermoid carcinoma of the parotid gland.

BMC Cancer. 2019-5-3

[4]
Oncologic outcome of parotid mucoepidermoid carcinoma in pediatric patients.

Cancer Manag Res. 2019-1-29

[5]
Adjuvant Chemotherapy Is Associated With Improved Survival for Late-Stage Salivary Squamous Cell Carcinoma.

Laryngoscope. 2019-4

[6]
Survival in patients with parotid gland carcinoma - Results of a multi-center study.

Am J Otolaryngol. 2018

[7]
Cyclical hypofractionated radiotherapy also known as "QUAD Shot" alone using intensity-modulated radiotherapy for squamous cell carcinoma of the parotid gland in an 85-year-old patient with multiple comorbidities.

Head Neck. 2017-4

[8]
Salivary gland tumours in a northern Chinese population: a 50-year retrospective study of 7190 cases.

Int J Oral Maxillofac Surg. 2017-3

[9]
Cyclical hypofractionated radiotherapy technique for palliative treatment of locally advanced head and neck cancer: institutional experience and review of palliative regimens.

J Community Support Oncol. 2016-1

[10]
Outcomes of Primary Squamous Cell Carcinoma of Major Salivary Glands Treated by Surgery With or Without Postoperative Radiotherapy.

J Oral Maxillofac Surg. 2015-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索